Skip to main content

Table 3 Baseline clinical and pathological characteristics of validation cohort B

From: New risk score for predicting steroid resistance in patients with focal segmental glomerulosclerosis or minimal change disease

Clinical variable No responseResponseOR (95% CI)a
N (%) 25 (42.4)34 (57.6)
Age (year) 49.7 ± 17.459.9 ± 14.70.96 (0.93–0.995)*
Gender (male %) 19 (76.0)20 (58.8)0.45 (0.14–1.42)
MAP (mmHg) 103.8 ± 14.0101.8 ± 12.41.01 (0.97–1.05)
BMI (kg/m2) 25.6 ± 3.024.7 ± 3.21.11 (0.93–1.32)
Ln(Pro) (g/24 h) 2.0 ± 0.41.8 ± 0.42.76 (0.75–10.16)
Albumin (g/L) 19.0 ± 4.718.3 ± 4.11.04 (0.92–1.17)
eGFR (mL/min/1.73 m2) 91.1 ± 24.687.3 ± 28.11.01 (0.99–1.03)
TG (mmol/L) 2.8 ± 1.33.5 ± 3.60.91 (0.72–1.14)
TC (mmol/L) 7.9 ± 2.98.0 ± 1.40.96 (0.75–1.23)
Ln(β2-MG/uCr) (ug/mmol) 3.8 ± 2.23.4 ± 1.51.15 (0.84–1.57)
Pathological evaluationScoreNo responseResponseOR (95% CI)
MN (%) 2534 
Global sclerosis (%)013 (52.0)9 (26.5)-ref-
112 (48.0)25 (73.5)0.33 (0.11–0.99)
Segmental sclerosis (%)023 (92.0)31 (91.2)-ref-
12 (8.0)3 (8.8)0.90 (0.14–5.82)
Interstitial fibrosis (%)03 (12.0)3 (8.8)-ref-
122 (88.0)31 (91.2)0.71 (0.13–3.85)
Inflammatory cell infiltration (%)01 (4.0)4 (11.8)-ref-
124 (96.0)30 (88.2)3.20 (0.33–30.55)
Tubular atrophy (%)03 (12.0)4 (11.8)-ref-
122 (88.0)30 (88.2)0.98(0.20–4.82)
Vascular lesion (%)010 (40.0)7 (20.6)-ref-
115 (60.0)27 (79.4)0.39 (0.12–1.23)
  1. MAP: mean arterial pressure; BMI: body mass index; Ln(Pro): natural logarithm of urine protein; eGFR: estimated glomerular filtration rate; TG: triglyceride; TC: total cholesterol; β2-MG: β2-microglobulin; α1-MG: α1-microglobulin; uCr: urinary creatinine; FSGS: focal segmental glomerulosclerosis; MCD: minimal change disease; IgAN: Immunoglobulin A nephropathy; MN: membranous nephropathy
  2. a Adjusted by age and gender
  3. *P < 0.05, #P < 0.01